Your browser doesn't support javascript.
loading
Adenosine-rich extract of Ganoderma lucidum: A safe and effective lipid-lowering substance.
Li, He; Du, Yawei; Ji, Hanrui; Yang, Yanan; Xu, Changchang; Li, Qiaodan; Ran, Longkai; Wu, Chongming; Zhou, Qile; Wu, Shengxian.
Afiliação
  • Li H; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Du Y; Shandong University of Traditional Chinese Medicine, Shandong 250355, China.
  • Ji H; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Yang Y; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Xu C; Pharmacology and Toxicology Research Center, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China.
  • Li Q; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Ran L; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Wu C; Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
  • Zhou Q; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
  • Wu S; Beijing Institute of Nutritional Resources, Beijing Academy of Science and Technology, Beijing 100069, China.
iScience ; 25(11): 105214, 2022 Nov 18.
Article em En | MEDLINE | ID: mdl-36281450
ABSTRACT
Ganoderma lucidum is a traditional Chinese medicine with a variety of active compounds and possesses adequate lipid-lowering and anti-atherosclerotic effects. However, its main active components and potential mechanisms still remain unclear. Here, we evaluated the anti-hyperlipidemic effect of the adenosine extract from Ganoderma lucidum (AEGL) in high-fat-diet (HFD)-induced hyperlipidemic ApoE-/- mice and explored the underlying biological mechanism by multi-omics analysis. Treatment with AEGL for 8 weeks significantly decreased the serum levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-c) by 45.59%, 41.22%, and 39.02%, respectively, as well as reduced liver TC and TG by 44.15% and 76.23%, compared with the HFD-only group. We also observed significant amelioration of hepatic steatosis without liver and kidney damage after AEGL treatment. Regulating the expression and acetylation/crotonylation of proteins involved in the PPAR signaling pathway may be one of the potential mechanisms involved in the observed lipid-lowering effects of AEGL.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China